ReviewCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2000
Pharmaceutical policies in Canada: another example of federal-provincial discord.
Review in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Impact of Tiered-Pricing Framework on Generic Entry in Canada.International journal of health policy and management · 2022Article
- Building a framework for the evaluation of knowledge translation for the Canadian Network for Observational Drug Effect Studies.Pharmacoepidemiology and drug safety · 2020Article
- The content of patient counseling about interchangeable medicines and generic substitution in Finnish community pharmacies - a survey of dispensers.BMC health services research · 2019Article
- How to pay for national pharmacare.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Article
- A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.Healthcare policy = Politiques de sante · 2016Article
- Pharmacists remuneration models in iran and selected countries: a comparative study.Iranian journal of pharmaceutical research : IJPR · 2013Article
- Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2011Article
- Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand.Healthcare policy = Politiques de sante · 2007Article
- The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada.Healthcare policy = Politiques de sante · 2007Article
- Public drug plan coverage for children across Canada: a portrait of too many colours.Healthcare policy = Politiques de sante · 2005Article
- Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.PharmacoEconomics · 2002Review
- Children in need of Pharmacare: medication funding requests at the Toronto Hospital for Sick Children.Canadian journal of public health = Revue canadienne de sante publiqueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical policy in Canada is set at both the federal and provincial levels of government. The federal government is responsible for intellectual property rights of manufacturers (patents) and the initial approval and labelling of prescription drugs and for ensuring overall market competitiveness. The provincial government has responsibility and jurisdiction over the funding of all health care services, including pharmaceuticals. Various interactions between the pharmaceutical industry, the federal and provincial governments and consumers have shaped the current landscape for prescription drugs in Canada. One key failing of the system is that the federal government is almost completely insulated from the impact of its policies because, although it regulates drug prices, it does not buy any drugs. In contrast, provincial governments have no jurisdiction over market competitiveness or pricing, yet end up paying for most of the drug expenditures incurred.
Indexed as
Identifiers
10701389PMC1231173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.